

BC PharmaCare Drug Information

The drug below is being considered for coverage under the BC PharmaCare program. PharmaCare is a government-funded drug plan that helps B.C. residents with the cost of eligible prescription drugs and medical supplies. For more information about PharmaCare, visit the [PharmaCare website](#).

PharmaCare reviews each drug for treating a specific illness or medical condition (also called an “indication”). If PharmaCare decides to cover a drug, that coverage applies only to the indication(s) specified. In some cases, PharmaCare covers a drug only for people who have not responded to other drugs that treat the same indication.

More information about the PharmaCare drug review process is provided on the last page of this document.

Drug information	
Generic name (scientific name)	garadacimab
Brand name	Andembry®
Manufacturer	CSL Behring Canada Inc.
Indication	Garadacimab is indicated for the routine prevention of attacks of hereditary angioedema (HAE) in adults and pediatric patients (aged 12 years and older).
Has the drug been reviewed by CDA-AMC, or will CDA-AMC be reviewing it? (See note below.)	Yes For more information about the CDA-AMC Reimbursement Review (CRR) of garadacimab (Andembry), Search the CDA-AMC Reports .
Public input start date	Wednesday, November 20, 2024
Public input closing date	Tuesday, December 17, 2024, at 11:59 pm
How is the drug taken?	Garadacimab is taken as a subcutaneous (under the skin) injection, where a needle injects the drug into the tissue layer between the skin and muscle.
How often is the drug taken?	Garadacimab is taken twice on the initial day of treatment, followed by once a month.

Drug information	
General drug and/or drug study information	<p>Garadacimab is a medicine that helps prevent hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and older.</p> <p>HAE is a rare genetic disease that affects how well the immune system controls swelling. It causes repeated episodes of severe swelling of the skin, airway, and gastrointestinal system.</p> <p>Garadacimab works by blocking the cascade of events leading to an HAE attack. Specifically, it inhibits the overproduction of bradykinin in the bloodstream. Too much bradykinin in the bloodstream can lead to a hereditary angioedema attack, with symptoms such as swelling and pain. Attacks may involve areas such as, the face, extremities, genitals, gastrointestinal tract, or the throat. Hereditary angioedema attacks can be fatal if swelling occurs in the throat area.</p> <p>Studies looked at the following:</p> <ul style="list-style-type: none"> • Number and type of HAE attacks • Subject’s Global Assessment of Response to Therapy at 6 months • Patient-reported quality of life measured by the Angioedema Quality of Life questionnaire and other scores • Bad reactions • Serious bad reactions • Patients leaving the trial due to bad reactions • Bad reactions of special interest, including thromboembolic events, bleeding events and severe hypersensitivity or anaphylaxis
Other considerations	None

Note:

CDA-AMC ([Canada’s Drug Agency-L’Agence des Médicaments du Canada](#)) is a national organization that reviews drugs on behalf of Canadian public sector plans when drug manufacturers want those plans to provide coverage for the drug. For detailed information about the PharmaCare drug review process, including the role of the CDA-AMC Reimbursement Review (CRR) in that process, visit [How PharmaCare Decides Which Drugs to Cover](#).

Cost of the drug compared to other drugs used to treat the same indication				
Generic Name (Brand Name) of Drug Comparator	PharmaCare Status (if and how the drug is already covered)	Dosage Form	Usual Dose	Cost of Therapy^a
garadacimab (Andembry)	Under Review	Solution for subcutaneous (SC) injection	Two injections on the first day of treatment, followed by once a month	TBC
<i>Indicated for prophylactic use in HAE</i>				
berotralstat (Orladeyo)	Exceptional case-by-case coverage through the PharmaCare EDRD program	Oral capsule	Once daily	\$310,463
lanadelumab (Takhzyro)	Exceptional case-by-case coverage through the PharmaCare EDRD program	Solution for SC injection	Once every two weeks, followed by every four weeks if patient is well-controlled for more than 6 months	\$533,988 if taken every 2 weeks \$266,994 if taken monthly
C1 esterase inhibitor (Haegarda)	Available through Canadian Blood Services	Powder for solution with diluent for SC injection	60 units/kg 3 to 4 days	\$509,524 to \$679,365
<i>Not indicated for prophylactic use in HAE</i>				

^a All prices taken from CDR Pharmacoeconomic Review Report for Garadacimab unless otherwise specified.

Cost of the drug compared to other drugs used to treat the same indication				
Generic Name (Brand Name) of Drug Comparator	PharmaCare Status (if and how the drug is already covered)	Dosage Form	Usual Dose	Cost of Therapy ^a
C1 esterase inhibitor (Berinert)	Available through Canadian Blood Services	Powder for solution with diluent for SC injection	20 units/kg once every 3 to 4 days	\$508,915 to \$678,553
		Powder for solution with diluent for intravenous (IV) injection	60 units/kg once every 3 to 4 days	\$1,526,744 to \$2,035,659

^a All prices taken from CDR Pharmacoeconomic Review Report for Garadacimab unless otherwise specified.

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called [Canada's Drug Agency-L'Agence des médicaments du Canada \(CDA-AMC\)](#)
- what the drug costs and whether it is a good value to the citizens of B.C.
- ethical considerations related to covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- existing PharmaCare policies, programs and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare to treat similar medical conditions
- the overall cost of covering the drug

For more information about the drug review process in B.C., visit: the [How PharmaCare decides which drugs to cover](#).

This document provides information only.

It does not take the place of advice from a physician or other qualified health care provider.